STAT+: Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits
Why it matters: The bill could impact drug affordability for Colorado taxpayers and patients, potentially preserving profits for pharmaceutical companies.
- Pharma companies and patient groups are pushing for a bill to exempt orphan drugs from Colorado's Prescription Drug Affordability Board pricing limits, citing concerns over patient access if companies halt sales.
- Opponents and consumer advocates argue the exemption would extend to many big-selling medicines for common conditions that also hold an orphan designation, increasing costs for countless patients and preserving drug company profits at taxpayer expense.
- The Colorado legislature is considering this bill for the second time in two years, with its outcome being closely watched by other states considering similar drug pricing regulations.
Colorado is again debating a bill to exempt orphan drugs from state pricing caps, sparking a contentious debate between patient advocates and consumer groups. While proponents argue the exemption is crucial for patient access to rare disease treatments, opponents warn it could inflate drug costs for many common conditions due to regulatory loopholes.
